美股市場個股詳情

ALLK Allakos

添加自選

1.020
+0.010+0.99%

收盤價 04/26 16:00 (美東)

1.070
+0.050+4.90%

盤後 19:50 (美東)

9031.54萬總市值-476市盈率TTM

Allakos股票討論區

登錄發表評論

71143235

03/02 02:59

$Allakos(ALLK.US)$ mark my words buyout rumors or news in 2-3 months

JCBF

02/01 18:18

still think it will be heading back to price gap

$Allakos(ALLK.US)$ Allakos | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.8%)
SEC announcement
·
01/29 17:30

JCBF

01/29 11:05

interesting

$Allakos(ALLK.US)$ huge price gap, will it make it back to 2.0?

Cool3r

01/16 21:26

Holly S plunged

$Allakos(ALLK.US)$

Trytosaveabit

01/16 20:15

$Allakos(ALLK.US)$ Allakos Announced Topline Data From Its Phase 2 Trial For Lirentelimab In Atopic Dermatitis (ATLAS) And Phase 2B Study In Chronic Spontaneous Urticaria (MAVERICK); The Studies Did Not Meet Their Primary Endpoints

Meltyy

01/03 20:11

Upcoming Ph 2 readouts in Q1 2024…

$Cellectar BioSciences(CLRB.US)$ Phase 2
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$阿里拉姆制藥(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...

Moomoo AI

2023/12/05 18:12

Allakos' 57% reduction in cash burn exhibits resilience, yet it's a high-risk stock due to large cash burn in comparison to market value. Future growth funding may cause substantial share dilution. The firm's ability to secure more funds and its future business growth are key considerations.